Europe Cannabidiol Market Size, Share, Growth, Analysis, Forecast and outlook (2023-2030)

Europe Cannabidiol Market Overview

The Europe Cannabidiol Market is exhibiting a CAGR of 18.8% during the forecast period (2023-2030).

Cannabis plants include cannabinoids like cannabidiol (CBD) and tetrahydrocannabinol (THC). CBD is the main ingredient in hemp and marijuana. Medical usage of cannabidiol is common owing to its health advantages. It treats epilepsy, anxiety, depression, insomnia, chronic pain, cancer-related pain, Parkinson's, Crohn's, schizophrenia, and other conditions.

Food, wellness, personal care, cosmetics, and others utilize cannabidiol in addition to medicinal purposes. CBD comes in gels, gummies, oils, supplements, extracts, and more.

Download free sample

Cannabidiol Market Dynamics in Europe:

Increased demand for cannabidiol products, growing prevalence of neurological ailments, psychiatric disorders, and chronic diseases, and increased legalizations and product approvals in different European nations are driving the development of the European cannabidiol market. Furthermore, rising demand for cannabidiol edibles will likely drive market growth throughout the forecast period.

Increased legalization and product approvals for CBD products are likely to propel the European cannabidiol industry forward.    

Cannabidiol products have recently become quite popular due to their medical qualities. Several firms are working hard to legalize cannabis and its derivatives in order to create new goods that will bridge the demand-supply gap for cannabidiol products.

For example, GW Pharmaceuticals Plc, a global company focused on discovering, developing, and delivering regulatory-approved cannabis-based medicines, announced in April 2021 that the European Commission (EC) approved the Type II variation application for EPIDYOLEX (cannabidiol) as an adjunctive treatment of seizures associated with Tuberous sclerosis complex (TSC) in patients two years of age and older. This approval, the third for GW's cannabidiol in Europe, opens the door to the medication's broader distribution throughout the continent. 

Europe Cannabidiol Market Segmentation

Over the course of the projection period, the isolation sector is anticipated to have the greatest CAGR (2023–2030).

The extract, full-spectrum, broad-spectrum, and other segments make up the Europe cannabinoid market. In 2022, the isolate category had the highest market share among all of these. This is mostly because of its advantages in treating mental illnesses such as anxiety, depression, PTSD, sleep difficulties, opioid withdrawal, and other mental diseases.

To Know More Insights: https://www.datamintelligence.com/research-report/europe-cannabidiol-market

Europe Cannabidiol Companies 

Some of the key players contributing to the growth of the market are Akanda Corporation, Aurora Cannabis Inc., Aphria Inc., Brains Bioceutical Corporation, ENDOCA, Elixinol, NuLeaf Naturals LLC, Cannoid LLC, Isodiol International Inc., and Medical Marijuana Inc.

Related Reports:

Dronabinol Market 

Cannabidiol (CBD) Market 

Ranitidine Market

Legalized Cannabis Market 

About Us

DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

Contact Us

Company Name: DataM Intelligence

Email: info@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com